{
  "id": "pharmacodynamics",
  "title": "Pharmacodynamics",
  "lang": "en",
  "source_lang": "en",
  "summary": "Pharmacodynamics studies how drugs produce biological effects, relating target interactions and drug concentrations to therapeutic responses, adverse effects, and changes over time.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Drug dynamics"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/pharmacodynamics/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/pharmacodynamics/",
      "json": "https://aiwiki.page/zh/pharmacodynamics.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Pharmacodynamics is the branch of pharmacology concerned with the biochemical and physiological effects of drugs and the mechanisms by which those effects occur. It examines how a drug interacts with biological targets, how those interactions alter cellular and organ function, and how the magnitude and duration of a response depend on drug concentration. Its subject includes beneficial effects, adverse effects, and actions on microorganisms or other disease-causing agents.\n\nPharmacodynamics is commonly distinguished from pharmacokinetics, which describes drug absorption, distribution, metabolism, and elimination. The distinction is often expressed as what a drug does to the body versus what the body does to a drug. In practice, the two are inseparable: pharmacokinetics determines the concentration reaching a site of action, while pharmacodynamics determines the response to that concentration. Together they provide a quantitative basis for understanding why the same dose can have different effects in different people.\n\nThe field connects molecular interactions with clinical outcomes. Its central concepts include affinity, efficacy, potency, selectivity, concentration–response relationships, and time-dependent changes in responsiveness. These concepts support the interpretation of experiments, the evaluation of medicines, and the design of studies that distinguish biological activity from clinically meaningful benefit."
    },
    {
      "heading": "Biological targets and mechanisms of action",
      "text": "Most drugs act by interacting with specific biological molecules, although some produce effects through broader physical or chemical processes. A drug target is a molecular structure whose interaction with a drug contributes to a biological response. Targets commonly include receptors, enzymes, ion channels, and transporters. Many are proteins, but nucleic acids and other cellular constituents can also be targets. Identifying a target does not, by itself, establish the full mechanism of action: the consequences of engaging that target depend on its location, physiological role, and connections to other processes.\n\nA drug receptor recognizes a ligand and translates binding into a change in cellular activity. G protein-coupled receptors can regulate second messengers, ion channels, and enzyme activity. Ligand-gated ion channels change membrane conductance when a ligand binds. Receptor tyrosine kinases initiate phosphorylation networks, whereas nuclear receptors regulate transcription after interacting with suitable ligands. These mechanisms operate on different timescales. Opening an ion channel can alter electrical activity within milliseconds, while changes in gene expression generally require longer to influence protein abundance and tissue function.\n\nDrugs acting on enzymes may inhibit catalysis reversibly or irreversibly. Aspirin, for example, acetylates cyclooxygenase, reducing the synthesis of prostanoids. Ion-channel drugs may obstruct a pore, alter channel gating, or stabilize a particular channel state. Transporter inhibitors change the movement of substances across membranes: a selective serotonin reuptake inhibitor reduces serotonin uptake through its transporter, while an SGLT2 inhibitor reduces glucose reabsorption in the kidney. These actions illustrate how similar outcomes can arise through different molecular routes and how one molecular action can affect several physiological functions.\n\nSome medicines work without a conventional receptor. Antacids neutralize acid through chemical reactions; osmotic agents change water movement by altering solute concentrations; chelators bind particular metal ions. Antimicrobial drugs often act on structures or pathways that differ between pathogens and their hosts. A beta-lactam antibiotic, for example, interferes with bacterial cell-wall synthesis by binding penicillin-binding proteins.\n\nA mechanism of action therefore spans several levels: initial interaction, cellular response, tissue effect, and clinical consequence. These levels should not be treated as interchangeable. Demonstrating enzyme inhibition in a purified preparation does not prove that sufficient inhibition occurs in living tissue, and demonstrating tissue activity does not necessarily establish improvement in symptoms, function, or survival."
    },
    {
      "heading": "Binding, affinity, and receptor occupancy",
      "text": "Drug binding is often described using the reversible interaction of a drug, \\(D\\), with a receptor, \\(R\\), to form a complex, \\(DR\\):\n\n\\[D+R \\rightleftharpoons DR.\\]\n\nFor a simple, noncooperative system at equilibrium, the fraction of receptors occupied is\n\n\\[f_{\\mathrm{occupied}}=\\frac{[D]}{K_D+[D]},\\]\n\nwhere \\([D]\\) is the free drug concentration at the receptor and \\(K_D\\) is the equilibrium dissociation constant. When \\([D]=K_D\\), half the receptors are occupied. A smaller \\(K_D\\) indicates higher binding affinity under the specified experimental conditions. The equation assumes a uniform population of independent binding sites and that drug binding does not substantially deplete the measured free concentration.\n\nAffinity describes binding, not the ability to generate a response. Two drugs can have similar affinity but markedly different functional effects. A drug may occupy a receptor and activate it strongly, activate it weakly, prevent another ligand from activating it, or reduce activity that occurs without an added ligand. Binding measurements therefore need to be interpreted alongside functional experiments. They are also sensitive to conditions such as temperature, ionic composition, receptor conformation, and the presence of interacting proteins.\n\nEquilibrium measurements do not fully describe binding kinetics. In a simple one-step interaction,\n\n\\[K_D=\\frac{k_{\\mathrm{off}}}{k_{\\mathrm{on}}},\\]\n\nwhere \\(k_{\\mathrm{on}}\\) and \\(k_{\\mathrm{off}}\\) are association and dissociation rate constants. Drugs with the same equilibrium affinity can have different rates of association and dissociation. A slow dissociation rate can sustain target occupancy after the surrounding free concentration has fallen. In the simplest model, the mean residence time is \\(1/k_{\\mathrm{off}}\\), although real biological systems may involve multiple binding states, local rebinding, and changing target abundance.\n\nOccupancy and effect need not rise in direct proportion. A system has a receptor reserve, also called spare receptors, when its maximal measured response can be achieved without occupying all available receptors. Signal amplification can allow a relatively small occupied fraction to produce a large downstream response. Conversely, substantial occupancy may produce little functional change if the receptor is weakly coupled to the measured process.\n\nThe relevant concentration is generally the unbound concentration accessible to the target, not necessarily the total concentration measured in plasma. Binding to circulating proteins, restricted tissue access, intracellular accumulation, and active transport can separate plasma measurements from target-site exposure. These are pharmacokinetic influences, but they directly affect the interpretation of pharmacodynamic relationships."
    },
    {
      "heading": "Agonism, antagonism, and signaling selectivity",
      "text": "An agonist binds to a receptor and promotes a response. A full agonist can produce the maximal response available in a specified experimental system, whereas a partial agonist produces a lower maximum under the same conditions. This distinction depends on the system as well as the molecule. A compound may appear to be a full agonist in tissue with abundant receptors and efficient coupling but a partial agonist where receptors are fewer or signaling is less strongly amplified.\n\nPartial agonists can both stimulate receptors and reduce the response to a more efficacious agonist. When both compete for the same receptor population, the partial agonist occupies receptors that might otherwise be activated more strongly. Buprenorphine illustrates this behavior at the mu-opioid receptor. Its effects cannot be described simply as either activation or blockade: they depend on its concentration, the presence of other ligands, receptor availability, and the response being measured.\n\nA receptor antagonist prevents receptor activation by another ligand. In an ideal equilibrium system, a reversible competitive antagonist produces a parallel rightward shift of the agonist concentration–response curve without reducing the attainable maximum. Sufficient agonist can overcome the competition. Under the assumptions of simple competitive antagonism, the dose ratio is\n\n\\[DR=1+\\frac{[B]}{K_B},\\]\n\nwhere \\([B]\\) is antagonist concentration and \\(K_B\\) is its equilibrium dissociation constant. Schild analysis uses this relationship to examine whether experimental behavior is consistent with competitive antagonism and to estimate antagonist affinity.\n\nIrreversible antagonism and noncompetitive inhibition can reduce the maximum response, although receptor reserve may initially conceal that reduction. An inverse agonist differs from a neutral antagonist by reducing constitutive receptor activity—activity occurring without an added agonist. This distinction matters only in systems where constitutive activity is detectable. Many antihistamines commonly described as H1 receptor antagonists are more precisely characterized as inverse agonists.\n\nAllosteric ligands bind at sites distinct from the principal endogenous ligand-binding site. They can increase or decrease ligand affinity, signaling efficacy, or both. Their effects may vary with the activating ligand and measured pathway. Similarly, biased agonism describes the preferential activation of some receptor-linked pathways relative to others, compared with a reference ligand. Establishing bias requires careful control for receptor expression, amplification, assay timing, and other system effects. Pathway preference observed in a laboratory assay does not by itself establish a superior therapeutic or safety profile."
    },
    {
      "heading": "Concentration–response relationships and quantitative models",
      "text": "Pharmacodynamic experiments commonly relate drug concentration to a graded response, such as enzyme inhibition, airway relaxation, or a change in heart rate. A widely used model is the maximum-effect model:\n\n\\[E(C)=E_0+\\frac{E_{\\max}C}{EC_{50}+C},\\]\n\nwhere \\(E_0\\) is baseline effect, \\(E_{\\max}\\) is the maximum modeled change from baseline, and \\(EC_{50}\\) is the concentration producing half that change. For an inhibitory response, the modeled change is subtracted from baseline or represented with an appropriately signed parameter. The model describes a saturating relationship: progressively larger concentration increases produce progressively smaller increments in effect near the maximum.\n\nThe Hill form introduces a slope parameter, \\(n\\):\n\n\\[E(C)=E_0+\\frac{E_{\\max}C^n}{EC_{50}^{\\,n}+C^n}.\\]\n\nThe curve becomes steeper as \\(n\\) increases. Although the Hill equation arose from studies of cooperative binding, an estimated Hill coefficient in a whole-cell or clinical experiment does not automatically measure molecular cooperativity or the number of binding sites. It can also reflect multistep signaling, heterogeneous populations, thresholds, or features of the measurement method.\n\nPotency describes the concentration or dose required to produce a specified effect. For drugs tested using the same response measure and comparable conditions, a lower \\(EC_{50}\\) generally indicates greater potency. Efficacy, in this context, refers to the capacity to produce a response and is often represented by the maximum attainable effect. A more potent drug is not necessarily more efficacious, safer, or clinically preferable. These properties answer different questions.\n\nConcentration–response curves are often plotted against logarithmic concentration because concentrations may span several orders of magnitude. A hyperbolic relationship on a linear concentration axis then appears sigmoidal. Such plots make shifts in potency easier to visualize, but they do not remove the need to examine variability, measurement error, baseline drift, or incomplete sampling of the response range.\n\nGraded responses must also be distinguished from quantal responses. A quantal analysis records whether each individual meets a defined outcome, such as becoming free of a specified symptom during a measurement period. The median effective dose, \\(ED_{50}\\), then denotes the dose associated with that outcome in 50% of the population, rather than a half-maximal response within one individual. Population response curves combine biological variability with the chosen outcome definition. Their position and slope can therefore change when the population, observation period, or criterion for success changes."
    },
    {
      "heading": "Time-dependent effects, adaptation, and delayed responses",
      "text": "A drug’s effect does not always follow its plasma concentration immediately. A delay may occur because the drug must distribute to a remote site, because target binding is slow, or because the measured response requires downstream biological changes. Consequently, the same plasma concentration can be associated with different effects during the rising and falling phases of exposure. Plotting effect against concentration over time may produce a hysteresis loop rather than a single concentration–response curve.\n\nOne way to represent a distribution-related delay is an effect-compartment model:\n\n\\[\\frac{dC_e}{dt}=k_{e0}(C_p-C_e),\\]\n\nwhere \\(C_p\\) is plasma concentration, \\(C_e\\) is a hypothetical effect-site concentration, and \\(k_{e0}\\) describes equilibration. The compartment is often a modeling construct rather than an anatomically identifiable space. Its purpose is to represent temporal separation between measured exposure and response. It cannot, by itself, establish the biological cause of a delay, because different mechanisms may produce similar observed patterns.\n\nIndirect-response models describe drugs that alter the production or loss of a physiological mediator. If a response variable \\(R\\) is produced at rate \\(k_{\\mathrm{in}}\\) and removed at rate \\(k_{\\mathrm{out}}R\\), its baseline dynamics are\n\n\\[\\frac{dR}{dt}=k_{\\mathrm{in}}-k_{\\mathrm{out}}R.\\]\n\nA drug may inhibit or stimulate either process. Warfarin, for example, interferes with vitamin K recycling and thereby reduces the formation of functional vitamin K-dependent clotting factors. Its anticoagulant effect is delayed partly because previously formed factors must disappear according to their turnover rates. The delay is not adequately explained by the time required for warfarin to appear in plasma.\n\nRepeated exposure can also change responsiveness. Tolerance is a reduced response after repeated or sustained exposure; tachyphylaxis refers to a relatively rapid loss of responsiveness. Mechanisms include receptor phosphorylation, receptor internalization, changes in signaling proteins, depletion of releasable mediators, and compensatory physiological responses. Increased drug metabolism can also cause tolerance, but that mechanism is pharmacokinetic rather than pharmacodynamic. The distinction requires comparing responses at comparable target-site exposure.\n\nDrug effects may outlast measurable circulating drug when binding is irreversible or recovery requires new protein synthesis. Aspirin’s inhibition of platelet cyclooxygenase persists because platelets have little capacity to replace the inhibited enzyme. Conversely, compensatory adaptation can produce rebound effects after exposure ends. The duration of action therefore cannot be inferred from elimination half-life alone: target turnover, mediator turnover, tissue repair, and physiological feedback may all determine how rapidly function returns."
    },
    {
      "heading": "Therapeutic effects, adverse effects, and drug combinations",
      "text": "Therapeutic and adverse effects arise from the same general pharmacodynamic principles. An unwanted effect may result from excessive activity at the intended target, activity at an unintended target, or a downstream consequence in another organ system. For example, blockade of a receptor involved in disease may also disrupt its normal physiological function elsewhere. Such an effect is “on target” even when it occurs outside the intended tissue. Off-target effects instead involve interactions with other molecular structures.\n\nThe therapeutic index expresses a separation between doses producing desired and harmful outcomes. One conventional form is \\(TD_{50}/ED_{50}\\), the ratio of a median toxic dose to a median effective dose for specified outcomes. Historically, animal studies also used \\(LD_{50}/ED_{50}\\), incorporating lethality. These ratios are limited summaries: they do not capture the full slopes of the response curves, the seriousness or reversibility of toxicity, or the characteristics of vulnerable subgroups. A therapeutic window more broadly denotes an exposure range associated with an acceptable balance between benefit and harm in a defined setting.\n\nSelectivity is relative rather than absolute. A drug may preferentially affect one receptor subtype at low concentrations but engage additional targets as concentrations increase. Selectivity also depends on tissue distribution and signaling context. Salbutamol preferentially activates beta-2 adrenoceptors, but this does not imply that all of its effects are confined to airway smooth muscle. Molecular selectivity, organ selectivity, and clinical tolerability are related but distinct properties.\n\nPharmacodynamic interactions occur when one drug modifies another’s effects without necessarily changing its concentration. Combinations of opioids with other central nervous system depressants can increase sedation and respiratory depression. By contrast, pharmacokinetic interactions change exposure through processes such as altered metabolism or elimination. A single drug pair can exhibit both kinds of interaction, so observing an enhanced effect does not identify its mechanism.\n\nCombination effects are described as additive, synergistic, or antagonistic relative to a stated reference model. Loewe additivity and Bliss independence use different assumptions and can classify the same data differently. Synergy is therefore not simply any improvement over either component alone. Reliable analysis requires individual concentration–response curves, a defined null model, and combination measurements across suitable concentration ranges. In antimicrobial treatment and cancer therapy, combinations may influence several outcomes differently: enhanced activity against the disease can coexist with additive toxicity, overlapping adverse effects, or selection for resistant populations."
    },
    {
      "heading": "Biological variability and resistance",
      "text": "People differ in pharmacodynamic sensitivity even when drug concentrations are similar. Sources of variation include target abundance, receptor coupling, physiological feedback, age, disease state, prior exposure, and genetic differences. Pharmacokinetic variability must be separated from these effects wherever possible. An unusually large response to a standard dose may reflect increased exposure, increased tissue sensitivity, or both; a dose–response observation alone cannot distinguish them.\n\nPharmacogenomics examines how genetic variation contributes to drug response. Variants in genes encoding drug targets or signaling components can alter sensitivity, while variants in drug-metabolizing enzymes primarily affect pharmacokinetics. Warfarin provides a well-established example of both categories: variation in VKORC1, which encodes its principal target, contributes to differences in sensitivity, while variation in CYP2C9 can alter elimination. Genetic associations do not eliminate the contributions of age, interacting medicines, diet, and other clinical factors.\n\nDisease can alter the connection between target engagement and response. Insulin resistance involves reduced responsiveness to insulin in important target tissues, with contributions from receptor-associated signaling and downstream metabolic processes. In heart failure, sustained sympathetic activation can be accompanied by changes in adrenergic receptor expression and signaling. Such adaptations illustrate why pharmacodynamic behavior measured in healthy tissue may not accurately represent diseased tissue. Baseline physiological reserve also affects the clinical consequences of a given molecular perturbation.\n\nResistance in pathogens and malignant cells includes mechanisms that reduce drug binding, bypass the inhibited pathway, or maintain survival despite target inhibition. Antibiotic resistance may involve altered targets, drug-inactivating enzymes, reduced entry, or increased efflux. These mechanisms span the boundary between local drug exposure and pharmacodynamic sensitivity. In cancer, mutations can alter a drug-binding site, while activation of an alternative signaling pathway can weaken the relationship between inhibition of the original target and control of cell growth.\n\nResistance also evolves over time and across heterogeneous populations. Treatment can preferentially suppress sensitive cells while leaving less sensitive subpopulations to expand. Measurements averaged across a specimen may conceal small resistant groups, and sensitivity at one anatomical site may differ from that at another. For this reason, a pharmacodynamic parameter is not necessarily a permanent characteristic of a person, pathogen, or tumor. It is conditional on biological state, treatment history, the sampled population, and the endpoint being measured."
    },
    {
      "heading": "Experimental measurement and clinical development",
      "text": "Pharmacodynamic research uses methods ranging from purified-protein assays to whole-organism studies. Binding experiments estimate affinity and occupancy; enzyme assays measure catalytic activity; electrophysiology records changes in ion-channel function; and cellular assays measure events such as second-messenger production, phosphorylation, gene expression, or cell death. Each method captures a particular part of the mechanism. Results can differ because of receptor abundance, assay duration, substrate concentration, cell type, and the degree of downstream signal amplification.\n\nA biomarker can provide evidence that a drug has reached or influenced its intended biological pathway. Target occupancy measured by imaging, suppression of a signaling protein in a biopsy, and changes in a circulating mediator are examples of pharmacodynamic measurements. Their interpretation depends on specificity and relevance. A biomarker may demonstrate target engagement without establishing a sufficient magnitude or duration of effect, and measurements in accessible tissue may not reflect activity in the organ responsible for disease.\n\nA surrogate endpoint is used in place of a direct measure of clinical benefit and requires evidence appropriate to its intended context. Not every pharmacodynamic biomarker is a validated surrogate. Lowering a laboratory measurement does not automatically demonstrate improvement in survival, symptoms, or function. This distinction is central to drug development, because an apparently coherent mechanism can fail to produce net benefit when tested against clinically meaningful outcomes.\n\nClinical studies characterize exposure–response relationships for both desired and adverse effects. A randomized controlled trial can help distinguish drug effects from background changes, confounding, and the placebo effect. However, a simple association between measured concentration and outcome within a treated group may remain confounded: disease severity can affect both drug disposition and prognosis. Baseline measurements, repeated observations, appropriate controls, and explicit statistical assumptions are important when estimating pharmacodynamic parameters.\n\nModels integrating pharmacokinetics and pharmacodynamics can evaluate how dose schedules influence the magnitude and duration of response. For antimicrobial drugs, commonly studied exposure indices include the fraction of time that free concentration exceeds the minimum inhibitory concentration, the free-drug area under the concentration–time curve relative to that concentration, and the peak concentration relative to it. Their relevance depends on the drug, organism, and infection model. Minimum inhibitory concentration is an assay-defined measure of growth inhibition, not a direct measurement of drug exposure or activity throughout an infected human tissue."
    },
    {
      "heading": "Historical development and conceptual foundations",
      "text": "Modern pharmacodynamics emerged from the effort to explain drug action through experimentally testable interactions rather than through undifferentiated effects on whole organisms. Nineteenth-century physiological experiments helped localize drug effects to particular tissues and processes. Claude Bernard’s work on curare showed how paralysis could result from interference with transmission between nerve and muscle rather than from loss of the muscle’s intrinsic ability to contract. Such experiments established the importance of distinguishing the site of action from the visible final response.\n\nJohn Newport Langley’s studies of autonomic drugs and skeletal muscle led him to propose specialized “receptive substances” through which chemicals acted. Paul Ehrlich independently developed receptor and side-chain concepts in immunology and chemotherapy. Their formulations differed, but both helped establish the idea that selective biological action could arise from selective chemical interaction. These proposals preceded the isolation or sequencing of most molecular targets and were initially supported by functional behavior rather than direct structural observation.\n\nIn 1909, A. V. Hill applied quantitative reasoning to the relation between nicotine concentration and muscle response. A. J. Clark subsequently developed occupancy-based approaches to drug action, particularly in his 1933 book The Mode of Action of Drugs on Cells. These approaches connected pharmacology with the law of mass action and encouraged systematic comparison of concentration–response curves. Their explanatory power also exposed a central problem: receptor occupancy alone could not account for all differences in maximum response.\n\nIn the 1950s, E. J. Ariëns and R. P. Stephenson developed influential accounts of intrinsic activity and efficacy. Their work helped distinguish the ability to bind from the ability to activate a biological system and clarified the behavior of partial agonists. Heinz Otto Schild’s analysis of antagonism provided a quantitative method for investigating competitive receptor blockade. In 1983, James Black and Paul Leff introduced an operational model of agonism that explicitly connected receptor-level properties with the responsiveness of an experimental system.\n\nLater advances made targets directly observable through radioligand binding, molecular cloning, structural biology, and live-cell signaling measurements. These methods revealed receptor families, multiple conformations, interacting proteins, and pathway-specific responses that were inaccessible to early tissue experiments. Contemporary pharmacodynamics consequently combines molecular descriptions with system-level models. A single parameter such as affinity or \\(EC_{50}\\) remains useful, but its meaning depends on experimental conditions and the biological process measured; neither a precise molecular structure nor an excellent curve fit independently establishes how a medicine will affect clinical outcomes."
    }
  ],
  "links": [
    "pharmacology",
    "pharmacokinetics",
    "enzyme",
    "protein",
    "gene-expression",
    "aspirin",
    "beta-lactam-antibiotic",
    "antihistamine",
    "warfarin",
    "therapeutic-index",
    "salbutamol",
    "opioid",
    "cancer",
    "pharmacogenomics",
    "insulin-resistance",
    "antibiotic-resistance",
    "biomarker",
    "surrogate-endpoint",
    "drug-development",
    "randomized-controlled-trial",
    "placebo-effect"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}